Vasoactive intracavernous pharmacotherapy.
The use of vasoactive intracavernous pharmacotherapy for the treatment of impotence is rapidly expanding because of its effectiveness and the rarity of short-term complications. To minimize complications, careful selection of candidates, cautious dosage determination, and thorough instruction on injection technique are mandatory. Sustained erection should be treated with alpha-adrenergic agents after 4 to 6 hours. Frequent follow-up is mandatory after home injection begins to detect the development of penile abnormalities. Longer follow-up and additional studies are required to determine the types and incidences of long-term adverse effects of the technique.
D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000503:physiopathology; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections / Q000009:adverse effects / Q000379:methods; D008297:Male; D010208:Papaverine / Q000008:administration & dosage* / Q000009:adverse effects; D010410:Penile Erection / Q000187:drug effects; D010413:Penis; D010646:Phentolamine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D012646:Self Administration; D013997:Time Factors; D014666:Vasomotor System / Q000187:drug effects*
D010208:Papaverine; D010646:Phentolamine